The age of 20-≤71years old. Also, in the current study, 30 healthy people were taken as a control group. Findings of the current study revealed substantial variations between chronic kidney disease (CKD) levels. The results of the current study demonstrated significant differences in s. urea between studied groups. Whereas, s. urea levels in CKD patients (107.42±8.52), were demonstrated a significant (P≤0.05) elevated in compared to a control (19.35± 2.16). while, creatinine levels in CKD patients (6.81± 0.55) demonstrated a significant (P≤0.05) elevated in compared to a control (0.84± 0.19). T3 levels in the end stage (5.17± 0.14) indicated a significant (P≤0.05) reduced than in other CDK stages and control group (6.34±0.28). T4 levels in the end stage (7.17±0.14) were significantly lower (P≤0.05) than in other CDK stages and control group (10.44±0.31). Thyroid-stimulating hormone (TSH) levels in the end stage (2.83±0.12) increased significantly (P≤0.05) compared to other CDK stages and control group (1.52±0.24). In contrast, fibroblast growth factor 23 (FGF-23) levels in the end stage (184.03±17.31) increased significantly (P≤0.05) as compared to other CDK stages and control group (5.16±0.45). Cystatin C level in CKD patients (17.11±1.94) was demonstrated a significant (P≤0.05) elevated in compared to a control (8.04±0.37). It is concluded from the study that CKD patients suffer from hypothyroidism based on hormone concentrations. The study also revealed a negative correlation between FGF-23 and Cystatin C levels with eGFR in CKD patients.